CD4 and neoplasm: In summary, as an immune-activating preventive and therapeutic strategy, CpG/αOX40/cGAMP combined with a whole-cell vaccine has the unique ability to amplify tumor-specific CD4+ T cells, which improves anti-tumor sensitivity and long-term tumor recognition.